San Francisco annual report shows continued drop in new HIV infections
New US PrEP cost-effectiveness model finds drug prices will need to drop substantially if HIV risk rises, or if adherence is only moderate
No new HIV infections among Kaiser PrEP users, but data shows missed opportunities
One in seven people offered PrEP in African study start it immediately
PrEP use in US exceeds 100,000 in Gilead pharmacy survey
PrEP demand in England is rapidly accelerating – and most will want to join the trial
Dutch study finds out whether gay men prefer daily or on-demand PrEP
London gonorrhoea rates fall, and HIV rates falling in Australia as more join PrEP demo
